Meeting Newsroom
A phase 1b study found the maximum tolerated dose to be 600 mg alectinib twice daily plus 40 mg cobimetinib daily for patients with ALK-positive lung cancer.
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
Sacituzumab govitecan prolongs progression-free survival vs standard chemotherapy among previously untreated patients with locally advanced, unresectable or metastatic triple-negative breast cancer unable to undergo PD-1/PD-L1 inhibition, according to findings from the phase 3 ASCENT-03 trial.
